News Releases

 
News Releases
  Date Title and Summary View
Mar 1, 2017
MOUNTAIN VIEW, Calif., March 01, 2017 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), today announced that the Company's fourth quarter 2016 financial results will be released after market close on Tuesday, March 14, 2017. ChemoCentryx executive management will host a conference call beginning at 5:00 p.m. Eastern Time on March 14, 2017 to...
Feb 28, 2017
MOUNTAIN VIEW, Calif., Feb. 28, 2017 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the Cowen and Company 37th Annual Health Care Conference on Tuesday, March 7, 2017 at 10:00 a.m. ET. The conference will be held at the Boston Marriott Cop...
Feb 14, 2017
-- ChemoCentryx retains all rights in the United States and China; Vifor Pharma gains additional marketing rights in Asia, including Japan and Middle Eastern markets -- ...
Jan 20, 2017
MOUNTAIN VIEW, Calif., Jan. 20, 2017 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI) today announced the presentation of results from its immuno-oncology program at the American Society of Clinical Oncology (ASCO) 2017 Gastrointestinal Cancers Symposium being held January 19-21, 2017 in San Francisco, California. The presentation highl...
Jan 9, 2017
-- Company Initiates Phase III "ADVOCATE" Clinical Trial for Complement Receptor Inhibitor Avacopan in ANCA Vasculitis; Development Path Outlined in Rare Kidney Disease for Chemokine Receptor Inhibitor ‘CCX140' -- MOUNTAIN VIEW, Calif., Jan. 09, 2017 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), today provided a corporate upda...
Jan 4, 2017
MOUNTAIN VIEW, Calif., Jan. 04, 2017 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the 35th Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2017 at 12:00 p.m. PT. The conference will be held at the Westin St. Francis Ho...
Dec 22, 2016
- ChemoCentryx to retain commercialization rights in the United States and China, Vifor Pharma gains rights in all other markets - - ChemoC...
Nov 7, 2016
-- Preparing for the Initiation of Phase III Development with Complement 5a Receptor Inhibitor Avacopan (CCX168) for the Treatment of ANCA Vasculitis -- -- Reported Positive Data from Ongoing Pilot Phase II Trial of Avacopan in Patients with Atypical Hemolytic Uremic Syndrome -- -- Highlighted Positive Findings in Complement 3 Glomerulopathy ...
Nov 7, 2016
-- Oral presentation at the American Society of Nephrology (ASN) Kidney Week 2016 to highlight Phase II AAV CLEAR trial results -- -- Oral presentation at the American College of Rheumatology (ACR) 2016 Annual Meeting to highlight Phase II AAV CLASSIC trial results -- MOUNTAIN VIEW, Calif., Nov. 07, 2016 (GLOBE NEWSWIRE) -- ChemoCentryx, In...
Oct 28, 2016
MOUNTAIN VIEW, Calif., Oct. 28, 2016 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), today announced that the Company's third quarter 2016 financial results will be released after market close on Monday, November 7, 2016. ChemoCentryx executive management will host a conference call beginning at 5:00 p.m. Eastern Time on November 7, 2016, ...
Page: FirstPrevious
2
... NextLast
= add release to Briefcase